EXACT Sciences Corporation (EXAS) has announced results for the company’s study regarding their Version 2 technology for colorectal cancer. This detailed study has consistent results with similar findings published earlier this year. For this reason, the final study results have been submitted for presentation at a major gastroenterology meeting scheduled to be held in 2008.
Steven Itzkowitz, M.D. and Professor of Medicine at Mount Sinai School of Medicine, stated, “The results of this study compared favorably to our interim findings and further demonstrated that the Version 2 technology for detecting colorectal cancer was highly reproducible in a large set of patients.”
This study evaluated sDNA in 82 patients with colorectal cancer and in 363 normal individuals. The study has shown that the company’s Version 2 technology demonstrated an 83 percent sensitivity in detecting cancers – the highest results of this kind. Interim results were published in the January 2007 issue of the American Gastroenterological Association’s journal, Clinical Gastroenterology and Hepatology.
“We are excited that these results are within the sensitivity range that was expected and we believe that they provide important validation of our Version 2 technology,” said Jeffrey R. Luber, President of EXACT Sciences Corporation. “We look forward to providing these final results to the American Cancer Society and the U.S. Multi-Society Task Force for Colorectal Cancer Screening, as well as to the Centers for Medicare and Medicaid Services in connection with our application for a National Coverage Determination.”
Let us hear your thoughts below: